Literature DB >> 7689810

TGF beta and HIV infection.

M Lotz1, P Seth.   

Abstract

TGF beta is a cytokine which is involved with the regulation of different aspects of host defense responses to injury. Overexpression of TGF beta can lead to the conversion of its protective functions to pathogenetic manifestations. TGF beta is a potent factor in promoting anabolic aspects in connective tissue metabolism, and uncontrolled production of TGF beta has been associated with the development of fibrosis. With respect to its effects on immune and inflammatory responses, TGF beta is an important endogenous immunosuppressive factor which physiologically may protect the organism from tissue damage caused by chronic activation of leukocytes. As a result of overproduction in HIV infection, this function of TGF beta can contribute to noncytopathic mechanisms of immunodeficiency. TGF beta is involved with several aspects of HIV disease and promotes virus replication and spreading through multiple distinct mechanisms. It directly stimulates virus replication in infected monocytes and peripheral blood mononuclear cells under certain in vitro conditions. It may stimulate the production of other cytokines that enhance virus replication and it may be the mediator of other HIV-stimulating agents such as cocaine. It enhances recruitment of mononuclear phagocytes as cells susceptible to virus infection. Through its profound and broad inhibitory effects on different antiviral defense mechanisms, it facilitates more rapid progression of virus infection and increases susceptibility to opportunistic infections and malignancies. Although these findings are largely based on in vitro systems, the demonstration of TGF beta overexpression in HIV-infected patients supports the notion that this cytokine is an important pathogenetic mediator in HIV infection and its associated diseases. Therapeutic strategies to interfere with these functions of TGF beta are the development of TGF beta-neutralizing antibodies and soluble TGF beta-binding proteins and receptors as well as approaches directed at reducing TGF beta gene expression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689810     DOI: 10.1111/j.1749-6632.1993.tb35912.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  24 in total

Review 1.  The Interactome of the Glucocorticoid Receptor and Its Influence on the Actions of Glucocorticoids in Combatting Inflammatory and Infectious Diseases.

Authors:  Ioanna Petta; Lien Dejager; Marlies Ballegeer; Sam Lievens; Jan Tavernier; Karolien De Bosscher; Claude Libert
Journal:  Microbiol Mol Biol Rev       Date:  2016-05-11       Impact factor: 11.056

2.  Transforming growth factor-beta 1 (TGF-beta1) expression in ovine lentivirus-induced lymphoid interstitial pneumonia.

Authors:  B Moreno; C J Woodall; N J Watt; G D Harkiss
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

3.  Detection of transforming growth factor-beta 1 in dermal lesions of different clinical forms of leprosy.

Authors:  I M Goulart; F Figueiredo; T Coimbra; N T Foss
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

4.  Elevated levels of circulating interleukin-18 in human immunodeficiency virus-infected individuals: role of peripheral blood mononuclear cells and implications for AIDS pathogenesis.

Authors:  Rasheed Ahmad; Sardar T A Sindhu; Emil Toma; Richard Morisset; Ali Ahmad
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 5.  Regulation of the Immune Response by TGF-β: From Conception to Autoimmunity and Infection.

Authors:  Shomyseh Sanjabi; Soyoung A Oh; Ming O Li
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-06-01       Impact factor: 10.005

Review 6.  Dendritic cells and natural killer cells in the pathogenesis of HIV infection.

Authors:  Claudio Fortis; Guido Poli
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

7.  Production of transforming growth factor-beta 1 (TGF-beta1) by blood monocytes from patients with different clinical forms of leprosy.

Authors:  I M Goulart; J R Mineo; N T Foss
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

Review 8.  Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  TGF-beta1 suppresses T cell infiltration and VP2 puff B mutation enhances apoptosis in acute polioencephalitis induced by Theiler's virus.

Authors:  Ikuo Tsunoda; Jane E Libbey; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2007-09-04       Impact factor: 3.478

10.  Perturbation of the natural killer cell compartment during primary human immunodeficiency virus 1 infection primarily involving the CD56 bright subset.

Authors:  Paola Mantegani; Giuseppe Tambussi; Laura Galli; Chiara Tassan Din; Adriano Lazzarin; Claudio Fortis
Journal:  Immunology       Date:  2009-08-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.